Katie Adams –
Tuesday, June 30th, 2020
The FDA will discuss its guidance on vaccine approval during a June 30 appearance before a Senate committee, according to The Wall Street Journal.
More articles on drug store: Cheap steroid in lack after being posited as possible COVID-19 treatmentNovartis pays DOJ, SEC $347M in kickback plan settlementPrices of 245 drugs treked in 6 months.
Stephen Hahn, MD, the firms commissioner, will provide the standards in a hearing before a Senate committee held to regulate the economys resuming.
To be approved, any vaccine must be at least 50 percent more reliable than a placebo and clearly demonstrate its safety in a scientific research study. The FDA will not authorize a vaccine if it only produces antibodies in clients blood, as the level of antibodies needed to guarantee protection versus COVID-19 is unidentified.
The FDA also told The Wall Street Journal it would need the drugmaker of any approved vaccine to monitor patients for a year after they get it.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.